首页> 外文OA文献 >Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes.
【2h】

Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes.

机译:甲状腺转录因子-1和细胞角蛋白20在鉴定宫颈淋巴结转移癌的起源中的效用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The identification of primary location of a metastatic tumor is a difficult diagnostic problem and sometimes can be facilitated by the use of immunohistochemical markers. Thyroid transcription factor-1 (TTF-1) is a 38-kDa nuclear homeodomain transcription factor that is expressed specifically in lung or thyroid neoplasms. Cytokeratin 20 (CK20) is a 46-kDa low-molecular-weight cytokeratin that shows restricted expression in adenocarcinomas of the gastrointestinal tract (GIT) and transitional cell carcinomas of the urinary tract. We studied the immunohistochemical expression of TTF-1 and CK20 in 68 metastatic carcinomas in cervical lymph nodes. The primary sites were the lung in 29 cases, stomach in 13, colorectum in 3, and other sites in 23. TTF-1 expression was detected in 69.0% of metastatic lung carcinomas and none in metastatic GIT carcinomas, whereas CK20 expression was detected in 68.8% of metastatic GIT carcinomas and none of metastatic lung carcinomas. TTF-1 had a specificity of 0.95 and a sensitivity of 0.69 for metastatic lung carcinoma, whereas CK20 had a specificity of 1.00 and a sensitivity of 0.69 for metastatic GIT carcinoma. These results indicate that TTF-1 and CK20 should be the first choice as a component of antibody panel to prove or to exclude the lung and GIT origin, respectively, especially in patients presenting with metastatic carcinomas of unknown primary site.
机译:转移性肿瘤的原发部位的鉴定是一个困难的诊断问题,有时可以通过使用免疫组织化学标记物来促进。甲状腺转录因子-1(TTF-1)是38 kDa的核同源结构域转录因子,在肺或甲状腺肿瘤中特异性表达。细胞角蛋白20(CK20)是一种46 kDa的低分子量细胞角蛋白,在胃肠道腺癌(GIT)和泌尿道移行细胞癌中表达受限。我们研究了68种转移性癌在宫颈淋巴结中TTF-1和CK20的免疫组织化学表达。主要部位是肺部29例,胃部13例,大肠癌3例,其他部位23例。转移性肺癌中69.0%检出TTF-1表达,转移性GIT癌中无TTF-1表达,而转移性GIT癌中检出CK20表达。 68.8%的转移性GIT癌,无转移的肺癌。 TTF-1对转移性肺癌的特异性为0.95,敏感性为0.69,而CK20对转移性GIT癌的特异性为1.00,敏感性为0.69。这些结果表明,TTF-1和CK20应该分别作为证明或排除肺和GIT起源的抗体组的首选,特别是在患有原发灶未知的转移性癌患者中。

著录项

  • 作者

    Roh, Mee Sook; Hong, Sook Hee;

  • 作者单位
  • 年度 2002
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类
  • 入库时间 2022-08-20 20:40:25

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号